Ardelyx Inc. (Nasdaq: $ARDX): The Growth Story Is No Longer Theoretical
Ardelyx is now a commercial-stage biotech where the core debate has moved from “can the product sell?” to “can the company turn rapid product growth into durable operating leverage?” That shift matters. It means $ARDX is no longer trading purely as a binary FDA story or early-launch hope. It is trading as a real revenue company with two approved U.S. products, a differentiated NHE3 biology platform, a growth engine in IBSRELA, a more complicated but still relevant kidney franchise in XPHOZAH, and a pipeline extension strategy that could make today’s commercial infrastructure more valuable over time.